NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
August 06 2020 - 6:00AM
Business Wire
Curated Menu of Off-the-Shelf RNAscope Probes
Provide Seamless Molecularly-Guided Region of Interest Selection
for Use With the New NGS-Enabled Cancer Transcriptome Atlas
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider
of life science tools for discovery and translational research, and
Bio-Techne (NASDAQ:TECH), a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic markets, today announced an expansion of their
partnership to include compatibility with ACD’s 21,000+ RNAscope
probes and 10 qualified RNAscope probe combinations with the GeoMx®
Digital Spatial Profiler (DSP) and the recently launched GeoMx
Cancer Transcriptome Atlas (CTA).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200806005332/en/
RNAscope™ multiplex fluorescent
visualization of cervical cancer. (Graphic: Business Wire)
A combined workflow has been previously developed that unites
the RNAscope reagent portfolio from Bio-Techne with NanoString’s
GeoMx RNA Assays to enable researchers to visualize RNA in tissue
at the single molecule level to molecularly guide their high-plex
spatial analyses on GeoMx DSP. Users can select any RNAscope probe
to visualize their FFPE or fresh frozen tissue morphology as an
alternative to antibody-based visualization. The full tissue image
generated by RNAscope probes is used for region of interest (ROI)
selection on GeoMx DSP for high-plex profiling. Ten new 2- or
3-plex qualified RNAscope probe combinations take this workflow one
step further, providing pre-qualified RNAscope reagents for use in
the joint workflow to ensure cross-assay compatibility. Selected
combinations cover key applications in immuno-oncology, including
targets difficult to detect with traditional antibodies, such as
chemokines, cytokines, immune checkpoints, and key immune cell
types.
“One of the top applications of RNAscope is immuno-oncology,
which is demonstrated by our large number of top tier publications
in this field. Spatial genomics is enabling key research,
broadening our understanding of disease mechanisms and pathology,
and we are proud to expand its utility through our continued
partnership with NanoString,” said Kim Kelderman, President
Diagnostics and Genomics Segment, Bio-Techne.
“This next step in our partnership pairs the best of RNAscope’s
immuno-oncology imaging content with the comprehensive profiling
coverage of the cancer transcriptome with CTA,” said Chad Brown,
SVP Sales and Marketing at NanoString. “The launch of the new
qualified probes provides an easy to use solution for the spatial
visualization and quantification of RNA.”
Users can select from the 10 qualified combinations plus any
user-defined probe from the broader RNAscope catalogue to guide
selection of ROI followed by profiling of tissue with the CTA. The
Cancer Transcriptome Atlas provides quantification of more than
1,800 genes covering 100 pathways critical to understanding tumor
biology, immune response and the tumor microenvironment, providing
a complete spatial view of cancer biology. RNAscope can then be
used downstream of GeoMx DSP analysis to confirm findings. The
combination of RNAscope’s unprecedented sensitivity, whole slide
coverage, and single cell resolution with the high multiplex gene
coverage of the GeoMx Cancer Transcriptome Atlas delivers an
industry leading assay that enables spatial quantitation.
Qualified RNAscope Probe Combinations are showcased in a joint
tech note.
https://www.nanostring.com/partnerships/partnerships-overview/geomx-partners/acd-partnership.
To learn more, visit:
https://acdbio.com/nanostring-partnership.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and
manufacturer of high-quality purified proteins and reagent
solutions - notably cytokines and growth factors, antibodies,
immunoassays, biologically active small molecule compounds, tissue
culture reagents and T-Cell activation technologies. Bio-Techne's
product portfolio also includes protein analysis solutions, sold
under the ProteinSimple brand name, offering researchers efficient
and streamlined options for automated western blot and multiplexed
ELISA workflow. These reagent and protein analysis solutions are
sold to biomedical researchers as well as clinical research
laboratories and constitute the Protein Sciences Segment.
Bio-Techne also develops and manufactures diagnostic products
including FDA-regulated controls, calibrators, blood gas and
clinical chemistry controls and custom assay development on
dedicated clinical instruments. Bio-Techne's genomic tools include
advanced tissue-based in-situ hybridization assays (ISH) for
research and clinical use, sold under the ACD brand as well as a
portfolio of clinical molecular diagnostic oncology assays,
including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate
cancer diagnosis. These diagnostic and genomic products comprise
Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products
are integral components of scientific investigations into
biological processes and molecular diagnostics, revealing the
nature, diagnosis, etiology and progression of specific diseases.
They aid in drug discovery efforts and provide the means for
accurate clinical tests and diagnoses. With thousands of products
in its portfolio, Bio-Techne generated approximately $739 million
in net sales in fiscal 2020 and has approximately 2,300 employees
worldwide.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science
tools for discovery and translational research. The company’s
nCounter® Analysis System is used in life sciences research and has
been cited in more than 3,500 peer-reviewed publications. The
nCounter Analysis System offers a cost-effective way to easily
profile the expression of hundreds of genes, proteins, miRNAs, or
copy number variations, simultaneously with high sensitivity and
precision, facilitating a wide variety of basic research and
translational medicine applications, including biomarker discovery
and validation. The company’s GeoMx® Digital Spatial Profiler
enables highly-multiplexed spatial profiling of RNA and protein
targets in a variety of sample types, including FFPE tissue
sections.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, GeoMx,
and nCounter are trademarks or registered trademarks of NanoString
Technologies, Inc. in various jurisdictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200806005332/en/
Doug Farrell, NanoString Vice President, Investor
Relations & Corporate Communications
dfarrell@nanostring.com Phone: 206-602-1768
David Clair, Bio-Techne Senior Director, Investor
Relations & Corporate Development David.Clair@bio-techne.com Phone:
612-656-4416
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024